Overview
Plain-language guide
Designed and approved for specific uses that include Type 2 diabetes, Chronic weight management, Cardiovascular risk reduction.
It copies a gut-hormone signal that helps the brain register fullness, slows stomach emptying and supports blood-sugar control.
Clinical mechanism
Activates the GLP-1 receptor to influence glucose-dependent insulin secretion, appetite and gastric emptying.
Applications
Human evidence
Multiple human studies and regulatory review support at least one product-specific indication.
Tier 1Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Muscle & recovery profile
Each signal is scored independently from 0–5. There is no composite “best” score.
Evidence classes
What has been studied
- Large human trials establish approved metabolic and weight-management outcomes; body-composition studies can track lean mass.
What is not established
- It is not designed for muscle growth, and weight reduction can include both fat and lean mass.
Studied populations
- Adults with type 2 diabetes
- Adults meeting approved chronic-weight-management criteria
Major limitations
- Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
- Findings from one population, formulation or indication should not be generalized to another.
Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.
Regulatory status
Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Novo Nordisk · Approved. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
August 5, 2026 · Primary-source check needed